Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Reported Tuberculosis in the United States, 2013

Return to Main Menu

(PDF - 195k)

Table 60. Tuberculosis Cases and Percentages by Completion of Tuberculosis Therapy (COT): Reporting Areas, 20111

Reporting Area Total Cases Therapy ≤1 Year Indicated2,3,4 Therapy >1 Year Indicated3,5 All Drug Therapy3
No. COT ≤1 Year(%) COT(%) No. COT(%) No. COT(%)
United States

10,509

8499

(89.0)

(95.7)

1036

(74.9)

9535

(93.5)

 
Alabama 161 138 (93.5) (98.6) 8 (75.0) 146 (97.3)
Alaska 67 53 (60.4) (64.2) 5 (80.0) 58 (65.5)
Arizona 255 166 (87.3) (95.8) 59 (67.8) 225 (88.4)
Arkansas 85 67 (83.6) (88.1) 3 (66.7) 70 (87.1)
California 2,323 1876 (87.3) (95.3) 218 (72.5) 2094 (92.9)
Colorado 70 59 (96.6) (96.6) 6 (83.3) 65 (95.4)
Connecticut 83 68 (94.1) (100.0) 7 (100.0) 75 (100.0)
Delaware 21 17 (94.1) (100.0) 4 (100.0) 21 (100.0)
District of Columbia 55 47 (80.9) (97.9) 4 (25.0) 51 (92.2)
Florida 754 607 (92.9) (98.4) 74 (77.0) 681 (96.0)
Georgia 347 277 (89.5) (96.8) 39 (59.0) 316 (92.1)
Hawaii 123 110 (90.0) (99.1) 6 (83.3) 116 (98.3)
Idaho 12 11 (81.8) (90.9) 1 (100.0) 12 (91.7)
Illinois 358 280 (91.4) (96.4) 45 (91.1) 325 (95.7)
Indiana 100 87 (89.7) (96.6) 7 (71.4) 94 (94.7)
Iowa 40 33 (84.8) (87.9) 7 (100.0) 40 (90.0)
Kansas 36 27 (88.9) (100.0) 5 (100.0) 32 (100.0)
Kentucky 70 56 (82.1) (96.4) 5 (80.0) 61 (95.1)
Louisiana 167 140 (82.9) (94.3) 12 (41.7) 152 (90.1)
Maine 9 8 (62.5) (62.5) 0 ... 8 (62.5)
Maryland 232 194 (94.8) (98.5) 21 (76.2) 215 (96.3)
Massachusetts 195 155 (83.9) (96.8) 24 (62.5) 179 (92.2)
Michigan 170 140 (89.3) (91.4) 19 (84.2) 159 (90.6)
Minnesota 137 101 (95.0) (96.0) 27 (63.0) 128 (89.1)
Mississippi 91 73 (91.8) (98.6) 4 (25.0) 77 (94.8)
Missouri 97 81 (91.4) (95.1) 7 (85.7) 88 (94.3)
Montana 8 7 (100.0) (100.0) 0 ... 7 (100.0)
Nebraska 23 20 (85.0) (90.0) 2 (50.0) 22 (86.4)
Nevada 96 82 (78.0) (82.9) 5 (100.0) 87 (83.9)
New Hampshire 11 10 (100.0) (100.0) 0 ... 10 (100.0)
New Jersey 331 253 (89.7) (96.8) 42 (78.6) 295 (94.2)
New Mexico 49 38 (92.1) (97.4) 4 (25.0) 42 (90.5)
New York State6 221 188 (94.1) (97.3) 15 (93.3) 203 (97.0)
New York City 684 565 (91.9) (96.8) 60 (81.7) 625 (95.4)
North Carolina 244 200 (95.5) (100.0) 21 (85.7) 221 (98.6)
North Dakota 7 5 (60.0) (60.0) 2 (50.0) 7 (57.1)
Ohio 145 118 (88.1) (92.4) 14 (85.7) 132 (91.7)
Oklahoma 94 72 (91.7) (100.0) 12 (100.0) 84 (100.0)
Oregon 74 64 (89.1) (96.9) 6 (100.0) 70 (97.1)
Pennsylvania 260 202 (85.1) (96.5) 28 (75.0) 230 (93.9)
Rhode Island 27 25 (80.0) (92.0) 1 (100.0) 26 (100.0)
South Carolina 140 113 (95.6) (97.3) 6 (83.3) 119 (96.6)
South Dakota 15 12 (83.3) (91.7) 2 (100.0) 14 (92.9)
Tennessee 156 131 (93.9) (97.7) 9 (66.7) 140 (95.7)
Texas 1,317 1074 (87.5) (94.6) 137 (71.5) 1207 (92.0)
Utah 34 25 (100.0) (100.0) 7 (100.0) 32 (100.0)
Vermont 8 6 (83.3) (100.0) 1 (0.0) 7 (85.7)
Virginia 221 190 (88.9) (96.8) 14 (71.4) 204 (95.1)
Washington 199 155 (85.2) (94.2) 25 (72.0) 180 (91.1)
West Virginia 13 10 (90.0) (100.0) 0 ... 10 (100.0)
Wisconsin 70 63 (87.3) (93.7) 6 (83.3) 69 (92.8)
Wyoming 4 4 (50.0) (50.0) 0 ... 4 (50.0)
 
American Samoa7 3 3 (0.0) (0.0) 0 ... 3 (0.0)
Fed. States of Micronesia7 142 130 (90.0) (91.5) 7 (85.7) 137 (91.2)
Guam7 80 72 (94.4) (97.2) 1 (100.0) 73 (97.3)
Marshall Islands7 148 143 (21.7) (21.7) 2 (0.0) 145 (21.4)
N. Mariana Islands7 31 29 (75.9) (86.2) 1 (0.0) 30 (83.3)
Puerto Rico7 50 34 (94.1) (97.1) 3 (100.0) 37 (97.3)
Republic of Palau7 8 7 (0.0) (0.0) 1 (0.0) 8 (0.0)
U.S. Virgin Islands7 0 0 -- -- 0 ... 0 --

1 Most recent year for which data are available.

2 Initial isolate susceptible to rifampin (n=6,293) or susceptibility unknown (n=102); culture negative (n=1,774); culture status unknown (n=330).

3 Number of cases in persons alive at diagnosis, with an initial regimen of one or more drugs prescribed, who did not die during therapy. Percentage for U.S. based on 52 reporting areas (50 states, New York City, and the District of Columbia). Percentages shown only for reporting areas with information reported for >90% of cases.

4 Therapy < 1 year indicated in persons alive at diagnosis with an initial regimen of one or more drugs prescribed, who did not die within one year of initiating therapy. Excludes persons with initial isolate rifampin resistant, or patient with bone and joint disease, meningeal disease or disease of the central nervous system, or pediatric patient (aged < 15) with miliary disease or positive blood culture, and those who moved out of the country within one year of initiating treatment.

5 Initial isolate rifampin resistant, or patient with meningeal disease, or pediatric patient (aged <15) with miliary disease or positive blood culture.

6 Excludes New York City.

7 Not included in U.S. totals.

Note: Ellipses indicate data not available. See Technical Notes for description of Completion of Therapy calculation (page 9).

Top